IDYA - IDEAYA Biosciences, Inc.
33.03
-1.650 -4.995%
Share volume: 664,634
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$34.68
-1.65
-0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-04-2024 | 02-18-2025 | 05-06-2025 | 08-05-2025 | 11-04-2025 | 02-17-2026 | |
| Assets | |||||||||
| Total Assets | 961.527 M | 973.663 M | 1.240 B | 1.124 B | 1.101 B | 1.041 B | 1.185 B | 1.109 B | |
| Current Assets | 709.353 M | 713.179 M | 932.214 M | 689.713 M | 707.872 M | 685.602 M | 802.655 M | 666.727 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 5.973 M | |
| Short Term Investments | 590.427 M | 518.609 M | 519.746 M | 591.941 M | 562.512 M | 555.093 M | 487.967 M | 526.563 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 108.345 M | 183.049 M | 400.283 M | 84.378 M | 129.996 M | 114.645 M | 298.927 M | 112.825 M | |
| Total Non-current Assets | 242.636 M | 251.071 M | 280.128 M | 405.832 M | 358.665 M | 322.131 M | 349.960 M | 410.297 M | |
| Property Plant Equipment | 6.909 M | 7.122 M | 8.235 M | 8.966 M | 8.871 M | 8.819 M | 8.172 M | 8.217 M | |
| Other Assets | 245.265 M | 253.362 M | 299.424 M | 425.412 M | 383.898 M | 346.849 M | 374.309 M | 434.380 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 961.527 M | 973.663 M | 1.240 B | 1.124 B | 1.101 B | 1.041 B | 1.185 B | 1.109 B | |
| Total liabilities | 26.216 M | 42.005 M | 59.455 M | 64.944 M | 76.506 M | 81.617 M | 93.102 M | 86.390 M | |
| Total current liabilities | 24.960 M | 40.742 M | 40.659 M | 46.071 M | 50.846 M | 55.338 M | 64.509 M | 58.815 M | |
| Accounts Payable | 6.290 M | 15.886 M | 12.567 M | 15.421 M | 17.631 M | 17.270 M | 18.433 M | 17.584 M | |
| Other liabilities | 1.256 M | 1.263 M | 18.796 M | 18.873 M | 25.660 M | 26.279 M | 26.917 M | 27.575 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 1.256 M | 1.263 M | 18.796 M | 18.873 M | 25.660 M | 26.279 M | 26.917 M | 27.575 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 935.311 M | 931.658 M | 1.180 B | 1.059 B | 1.024 B | 959.653 M | 1.092 B | 1.023 B | |
| Common stock | 1.324 B | 1.374 B | 1.669 B | 1.681 B | 1.718 B | 1.731 B | 1.743 B | 1.757 B | |
| Retained earnings | -387.936 M | -440.708 M | -492.529 M | -622.841 M | -695.019 M | -772.510 M | -653.266 M | -736.539 M |